Taysha Gene Therapies (TSHA) Total Current Liabilities (2019 - 2026)

Taysha Gene Therapies has reported Total Current Liabilities for 8 years, with the latest figure at $20.1 million in Q1 2026.

• Quarterly Total Current Liabilities fell 10.9% year-over-year to $20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.1 million (down 10.9% YoY) and the FY2025 annual result came in at $26.6 million, up 1.24% from the prior year.
• Total Current Liabilities declined to $20.1 million in Q1 2026 per TSHA's latest filing, from $26.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $180.5 million in Q3 2023 and troughed at $20.1 million in Q1 2026.
• A 5-year average of $44.8 million and a median of $34.2 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 444.53% in 2023, then tumbled 83.74% in 2024.
• Over 5 years, Total Current Liabilities stood at $62.8 million in 2022, then tumbled by 41.46% to $36.8 million in 2023, then fell by 28.65% to $26.2 million in 2024, then advanced by 1.24% to $26.6 million in 2025, then retreated by 24.31% to $20.1 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $20.1 million, $26.6 million, and $28.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.